
Advances in cell therapies for Parkinson’s, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs
2025-05-15
0:00
4:14
In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny.
Fler avsnitt från "Neurology Today in 5"
Missa inte ett avsnitt av “Neurology Today in 5” och prenumerera på det i GetPodcast-appen.